<DOC>
	<DOCNO>NCT00223171</DOCNO>
	<brief_summary>The objective study use reference 36-month duration hormonal therapy accord European Organization Research Treatment Cancer ( EORTC protocol 22863 ) : namely one-month total androgen blockade follow luteinizing hormone release hormone ( LHRH ) agonist , three year , combine pelvic prostate irradiation ; arm currently consider standard high-risk prostate cancer . The propose study intend challenge duration hormonal therapy verify whether five-year outcome favour combine treatment regard survival ( 79 % versus 62 % ) local control ( 85 % versus 48 % ) transpose hormonal therapy half long , namely 18 month , possibility hormone salvage therapy event biochemical and/or clinical failure ( local , regional , distant ) ; applies arm . The propose study compare survival two group evaluate one total duration initial hormonal therapy , follow initial hormonal therapy combine salvage hormonal therapy , duration salvage hormonal therapy hormonal therapy resistance , side effect hormonal therapy , everything related assessment quality life patient .</brief_summary>
	<brief_title>Duration Androgen Blockade Combined With Pelvic Irradiation Prostate Cancers</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>To least one follow three risk factor : Tumour classify T3 T4 Gleason score 810 Prostatespecific antigen ( PSA ) level &gt; 20 Performance status score 01 . Patients must sign consent form start study . No evidence regional disease : clinically negative regional adenopathy reveal imaging ( compute axial tomography [ CAT ] scan , magnetic resonance image [ MRI ] , lymphography ) surgical stag negative pelvic node dissection . No distant metastasis . These patient must negative bone scan 12 week prior randomization . Hormonal therapy allow maximum two month consent form sign , long initial workup do , include request deadline respect . Patients previous history cancer eligible condition disease progression five year . The patient must available treatment followup visit . Treatments must start three week follow randomization . Severe medical psychiatric problem could compromise study compliance . Chronic hepatic disease , abnormal hepatic function , i.e . aspartate aminotransferase , alanine aminotransferase &gt; 1.5 time upper normal limit .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Stage T3 T4</keyword>
	<keyword>PSA &gt; 20</keyword>
	<keyword>Gleason Score &gt; 7</keyword>
</DOC>